Project Details
Projekt
Molecular guided experimental treatments in patients with relapsed/ refractory lymphoid malignancies
Subject Area
Hematology, Oncology
Term
since 2022
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 444949889
The aim of the Z project is to establish a clinical platform and center of excellence for children and adults with r/r ALL who have a major medical need for novel therapeutic approaches. The framework structures to translate scientific knowledge to therapy decisions can only be carried out through a multidisciplinary board with experienced ALL experts holding experimental, preclinical and clinical expertise in the treatment of adult and pediatric ALL patients. Z will imply the organization of a lymphoid tumor board (CATCH ALL board) introducing molecular guided experimental treatments and immunotherapies in a structured and well documented manner. This will also incorporate many of the participating PIs of the other projects. In this context, the Z project is in a central role for connecting all projects of the clinical research unit. Z will be the platform for translating findings into clinical benefit and therefore connect the projects in a clinical setting. In the CATCH ALL board all participating scientists are taking part in clinical decisions. An important task will be to establish the link to the AIEOP-BFM and GMALL study groups. All discussed patients in the CATCH ALL board will be characterized on the molecular level, PDX models will be generated and drug testing performed. Furthermore, due to the infrastructural role of the Z project, the departments of hematology and oncology for pediatric and adult patients will closely collaborate in this project. Within this project, we will strengthen this existing cooperation through incorporation of rotation positions for physicians between the adult and pediatric departments. A further step towards an adolescent and young adult (AYA) unit will be the implementation of an outpatient clinic for AYA patients. In this regard, topics relevant to the treatment of AYA patients will be an essential part of clinical research unit meetings.
DFG Programme
Clinical Research Units
